Conference Call Scheduled for today,
November 14, 2023, at 5:00pm ET.
GARDNER,
Mass., Nov. 14, 2023 /PRNewswire/ -- Precision
Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and
manufacturer of advanced optical instruments for the medical and
defense industries, announced operating results on an unaudited
basis for its first quarter fiscal year 2024 for the period ended
September 30, 2023.
Q1 2024 Financial Highlights (3 Months Ended September 30, 2023):
- Revenue decreased 15% to $4.3
million, compared to $5.1
million in the same quarter of the previous fiscal
year.
- Production revenue was $2.4
million compared to $3.4
million in the same quarter of the previous fiscal
year.
- Engineering revenue was $1.9
million compared to $1.6
million in the same quarter of the previous fiscal
year.
- Gross margins were 33.9% compared to 32.2% in the same quarter
of the previous year.
- Net loss for the quarter was ($464,415), compared to a net loss of
($158,724) in the same quarter of the
previous year.
- Adjusted EBITDA was ($244,983)
for the quarter compared to $25,599
in the same quarter of the previous year.
Recent Additional Highlights:
- In November 2023, the Company
announced the receipt of an $890,000
initial production order for a complex imaging sub-assembly that
will be used in the customer's new robotic laparoscopy system.
The imaging subassembly incorporates cutting edge optical,
electronic, and mechanical systems designed by Precision
Optics.
- In October 2023, the Company
announced the receipt of an initial production order from a top
tier defense/aerospace company totaling $680,000 addressing a new commercial application
leveraging the Company's manufacturing IP developed for high
precision micro-optics technology.
Precision Optics' CEO, Joseph
Forkey, commented, "As anticipated and discussed last
quarter, the decline in revenue was attributable to timing
differences between the exit of certain mature customer programs,
reorders for ongoing products and the introduction of new customer
programs, primarily in the areas of medical endoscopes, including
single-use devices and new defense / aerospace commitments.
Revenue was also impacted by lower order volumes of optical
components from our Ross Optical operation as customers sought to
rebalance their inventories which had previously grown beyond
sustainable levels due to increased ordering in response to
concerns about supply chain disruptions. We believe reduced
customer demand to be transient, and we have already seen a second
quarter recovery in revenue levels both with Ross Optical and in
production. We continue to believe that revenue growth should
accelerate in the second half of this fiscal year as new programs
enter commercial production. Customer programs we're
producing have the market potential to support substantial
Precision Optics growth."
Dr. Forkey continued, "During the first quarter, engineering
revenue was close to the previous quarter's record level and was up
16% compared to the same quarter a year ago. We are starting to see
the positive results of the strong engineering pipeline we have had
for some time now, as new programs are beginning to move to
production, including two programs that we just announced in the
last month. We continue to focus on building sustainable value in
the business by engaging with customers at the onset of engineering
through to commercial production, leveraging our unique technical
resources and manufacturing capabilities to bring innovative new
applications to market. Our engineering pipeline remains robust and
we look forward to sustained growth in Fiscal 2024 and beyond."
The following table summarizes the fourth quarter and fiscal
year (unaudited) results for the periods ended September 30, 2023, and 2022:
|
|
Three Months
|
|
|
Ended September
30,
|
|
|
2023
|
2022
|
Revenues
|
$4,321,255
|
$5,085,301
|
|
|
|
|
Gross Profit
|
1,463,611
|
1,639,441
|
|
|
|
|
Stock Compensation
Expenses
|
108,746
|
74,990
|
Other
|
1,760,158
|
1,666,253
|
Total Operating
Expenses
|
1,868,904
|
1,741,243
|
|
|
|
|
Operating Income
(Loss)
|
(405,293)
|
(101,802)
|
|
|
|
|
Net Income
(Loss)
|
(464,415)
|
(158,724)
|
|
|
|
|
Income (Loss) per
Share
|
|
|
|
Basic and Fully
Diluted
|
$
(0.08)
|
$
(0.03)
|
|
|
|
Weighted Average Common
Shares Outstanding
|
|
Basic and Fully
Diluted
|
6,066,518
|
5,638,363
|
|
Note: The Common
Shares in this table reflect shares on a post reverse split basis
for all periods presented.
|
Conference Call Details
Date and Time:
Tuesday, November 14, 2023, at
5:00pm ET
Call-in Information: Interested parties can access the
conference call by dialing (844) 735-3662 or
(412) 317-5705.
Live Webcast Information: Interested parties can access
the conference call via a live webcast, which is available at
https://app.webinar.net/q7ndVdGzwyJ.
Replay: A teleconference replay of the call will be
available until November 21, 2023, at
(877) 344-7529 or (412) 317-0088, replay access code 1146933.
A webcast replay will be available at
https://app.webinar.net/q7ndVdGzwyJ.
About Precision Optics Corporation
Founded in 1982,
Precision Optics is a vertically integrated optics company
primarily focused on leveraging its proprietary micro-optics and 3D
imaging technologies to the healthcare and defense/aerospace
industries by providing services ranging from new product concept
through mass manufacture. Utilizing its leading-edge in-house
design, prototype, regulatory and fabrication capabilities as well
as its Lighthouse Imaging division's electronic imaging expertise
and its Ross Optical division's high volume world-wide sourcing,
inspecting and production resources, the Company is able to design
and manufacture next-generation product solutions to the most
challenging customer requirements. Within healthcare, Precision
Optics enables next generation medical device companies around the
world to meet the increasing demands of the surgical community who
require more enhanced and smaller imaging systems for minimally
invasive surgery as well as 3D endoscopy systems to support the
rapid proliferation of surgical robotic systems. In addition to
these next generation applications, Precision Optics has supplied
top tier medical device companies a wide variety of optical
products for decades, including complex endocouplers and
specialized endoscopes. The Company is also leveraging its
technical proficiency in micro-optics to enable leading edge
defense/aerospace applications which require the highest quality
standards and the optimization of size, weight and power. For more
information, please visit www.poci.com.
Non-GAAP Financial Measures
Precision Optics has provided in this press release financial
information that has not been prepared in accordance with
accounting principles generally accepted in the Unites States of
America ("non-GAAP"). The non-GAAP financial measure is Adjusted
EBITDA (earnings before interest, taxes, depreciation and
amortization). Adjusted EBITDA also excludes from Net Income (Loss)
the effect of stock-based compensation, restructuring and other
acquisition-related items.
This non-GAAP financial measure assists Precision Optics
management in comparing its operating performance over time because
certain items may obscure the underlying business trends and make
comparisons of long-term performance difficult, as they are of a
nature and/or size that occur with inconsistent frequency or relate
to discrete acquisition or restructuring plans that are
fundamentally different from the ongoing productivity of the
Company. Precision Optics management also believes that presenting
this measure allows investors to view its performance using the
same measures that the Company uses in evaluating its financial and
business performance and trends.
Non-GAAP financial measures should not be considered in
isolation from, or as a substitute for, financial information
calculated in accordance with GAAP. Investors are encouraged to
review the reconciliation of non-GAAP measures to their most
directly comparable GAAP financial measures. A reconciliation of
the non-GAAP financial measure presented above to GAAP results has
been provided in the financial tables included with this press
release.
About Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include, but are not limited to,
statements that express the Company's intentions, beliefs,
expectations, strategies, predictions or any other statements
related to the Company's future activities or future events or
conditions. These statements are based on current expectations,
estimates and projections about the Company's business based, in
part, on assumptions made by the Company's management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed or forecasted in the forward-looking statements
due to numerous factors, including those risks discussed in the
Company's annual report on Form 10-K and in other documents that we
file from time to time with the SEC. Any forward-looking statements
speak only as of the date on which they are made, and the Company
does not undertake any obligation to update any forward-looking
statement, except as required by law.
Company
Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts
01440-3338
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com
Following are the Company's Consolidated Balance Sheets at
September 30, 2023 and June 30, 2023, and Statements of Cash Flows, for
the three months ended September 30,
2023 and 2022:
CONSOLIDATED BALANCE
SHEETS (UNAUDITED)
|
|
|
|
|
|
|
|
|
|
September
30,
|
|
|
June
30,
|
|
|
|
2023
|
|
|
2023
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current
Assets:
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
1,370,469
|
|
|
$
|
2,925,852
|
|
Accounts receivable,
net of allowance for doubtful accounts of $690,097
at September 30, 2023 and $606,715 at June 30,
2022
|
|
|
4,533,126
|
|
|
|
3,907,407
|
|
Inventories
|
|
|
2,971,211
|
|
|
|
2,776,216
|
|
Prepaid
expenses
|
|
|
361,801
|
|
|
|
249,681
|
|
Total current
assets
|
|
|
9,236,607
|
|
|
|
9,859,156
|
|
|
|
|
|
|
|
|
|
|
Fixed
Assets:
|
|
|
|
|
|
|
|
|
Machinery and
equipment
|
|
|
3,243,496
|
|
|
|
3,227,481
|
|
Leasehold
improvements
|
|
|
842,455
|
|
|
|
825,752
|
|
Furniture and
fixtures
|
|
|
240,917
|
|
|
|
242,865
|
|
Total fixed
assets
|
|
|
4,326,868
|
|
|
|
4,296,098
|
|
Less—Accumulated
depreciation and amortization
|
|
|
3,914,142
|
|
|
|
3,862,578
|
|
Net fixed
assets
|
|
|
412,726
|
|
|
|
433,520
|
|
|
|
|
|
|
|
|
|
|
Operating lease
right-to-use asset
|
|
|
317,083
|
|
|
|
358,437
|
|
Patents, net
|
|
|
277,858
|
|
|
|
265,111
|
|
Goodwill
|
|
|
8,824,210
|
|
|
|
8,824,210
|
|
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$
|
19,068,484
|
|
|
$
|
19,740,434
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
Current
Liabilities:
|
|
|
|
|
|
|
|
|
Current portion of
capital lease obligation
|
|
$
|
43,859
|
|
|
$
|
43,209
|
|
Current maturities of
long-term debt
|
|
|
513,259
|
|
|
|
513,259
|
|
Accounts
payable
|
|
|
1,733,661
|
|
|
|
2,432,264
|
|
Customer
advances
|
|
|
1,424,983
|
|
|
|
1,174,690
|
|
Accrued compensation
and other
|
|
|
1,239,781
|
|
|
|
927,521
|
|
Operating lease
liability
|
|
|
171,075
|
|
|
|
168,677
|
|
Total current
liabilities
|
|
|
5,126,618
|
|
|
|
5,259,620
|
|
|
|
|
|
|
|
|
|
|
Capital lease
obligation, net of current portion
|
|
|
57,270
|
|
|
|
68,482
|
|
Long-term debt, net of
current maturities and debt issuance costs
|
|
|
2,047,665
|
|
|
|
2,175,980
|
|
Operating lease
liability, net of current portion
|
|
|
146,008
|
|
|
|
189,760
|
|
|
|
|
|
|
|
|
|
|
Stockholders'
Equity:
|
|
|
|
|
|
|
|
|
Common stock, $0.01 par
value: 50,000,000 shares authorized; issued and
outstanding – 6,066,518 shares at September 30,
2023 and June 30,
2023
|
|
|
60,665
|
|
|
|
60,665
|
|
Additional paid-in
capital
|
|
|
60,333,680
|
|
|
|
60,224,934
|
|
Accumulated
deficit
|
|
|
(48,703,422)
|
|
|
|
(48,239,007)
|
|
Total stockholders'
equity
|
|
|
11,690,923
|
|
|
|
12,046,592
|
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
$
|
19,068,484
|
|
|
$
|
19,740,434
|
|
PRECISION OPTICS
CORPORATION, INC. AND SUBSIDIARIES CONSOLIDATED
STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS
ENDED SEPTEMBER 30, 2023 AND
2022 (UNAUDITED)
|
|
|
|
|
|
|
|
|
|
Three Months
Ended September 30,
|
|
|
|
2023
|
|
|
2022
|
|
Cash Flows from
Operating Activities:
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(464,415)
|
|
|
$
|
(158,724)
|
|
Adjustments to
reconcile net loss to net cash used in by operating activities
-
|
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
51,564
|
|
|
|
52,411
|
|
Stock-based
compensation expense
|
|
|
108,746
|
|
|
|
74,990
|
|
Non-cash interest
expense
|
|
|
4,376
|
|
|
|
9,412
|
|
Changes in operating
assets and liabilities -
|
|
|
|
|
|
|
|
|
Accounts receivable,
net
|
|
|
(625,719)
|
|
|
|
(750,813)
|
|
Inventories,
net
|
|
|
(194,995)
|
|
|
|
266,487
|
|
Prepaid
expenses
|
|
|
(112,120)
|
|
|
|
25,950
|
|
Accounts
payable
|
|
|
(698,603)
|
|
|
|
151,945
|
|
Customer
advances
|
|
|
250,293
|
|
|
|
127,778
|
|
Accrued compensation
and other
|
|
|
307,884
|
|
|
|
400,298
|
|
Net cash (used in)
provided by operating activities
|
|
|
(1,372,989)
|
|
|
|
199,734
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from
Investing Activities:
|
|
|
|
|
|
|
|
|
Purchases of fixed
assets
|
|
|
(30,770)
|
|
|
|
(16,019)
|
|
Additional patent
costs
|
|
|
(12,747)
|
|
|
|
(13,155)
|
|
Net cash used in
investing activities
|
|
|
(43,517)
|
|
|
|
(29,174)
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from
Financing Activities:
|
|
|
|
|
|
|
|
|
Payment of capital
lease obligation
|
|
|
(10,562)
|
|
|
|
(9,950)
|
|
Payments of long-term
debt
|
|
|
(128,315)
|
|
|
|
(92,857)
|
|
Net cash used in
financing activities
|
|
|
(138,876)
|
|
|
|
(102,807)
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase
in cash and cash equivalents
|
|
|
(1,555,383)
|
|
|
|
67,753
|
|
PRECISION OPTICS
CORPORATION, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP
TO NON-GAAP FINANCIAL MEASURES ADJUSTED
EBITDA
|
|
|
|
Three Months
Ended June 30,
|
|
|
|
|
2023
|
|
|
2022
|
|
|
Net Income (loss)
(GAAP)
|
|
$
|
(464,415)
|
|
|
$
|
(158,724)
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock based
compensation
|
|
|
108,746
|
|
|
|
74,990
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
51,564
|
|
|
|
52,411
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
expense
|
|
|
59,122
|
|
|
|
56,922
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
(non-GAAP)
|
|
$
|
(244,983)
|
|
|
$
|
25,599
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precision-optics-reports-first-quarter-fiscal-year-2024-financial-results-301988119.html
SOURCE Precision Optics Corporation